Real-life data on tebentafusp in metastatic uveal melanoma patients from four EURACAN Expert Centres

Skin Cancer

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

Eur J Cancer

Dimitriou F, Orloff MM, Koch Hein EC, Cheng PF, Hughes IF, Simeone E, Montazeri K, Grover P, Mehmi I, Gerard CL, Gaudy-Marqueste C, Grob JJ, Michielin O, Hamid O, Long GV, Sullivan R, Kapiteijn E, Johnson DB, Ascierto PA, Joshua AM, Carvajal RD, Butler MO, Hassel JC, Dummer R

doi: 10.1016/j.ejca.2024.115161

SPECIAL REPORT

Breast Cancer

Results of TRODELVY^® real-world data

Skin Cancer

Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial

Ann Oncol

Ten Ham RMT, Rohaan MW, Egeler M, Menezes R, Holz Borch T, Kessels R, Jedema I, Nuijen B, Nijenhuis C, van de Poll-Franse LV, Geukes Foppen MH, Lindenberg M, Mansfield Noringriis I, Monberg TJ, Donia M, van Harten W, Svane IM, Haanen JBAG, Retèl VP

doi: 10.1016/j.annonc.2025.06.005

Skin Cancer

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Eur J Cancer

Amaral T, Nanz L, Higuita LMS, Ascierto P, Berking C, Couselo EM, Donia M, Dummer R, Gutzmer R, Haushild A, Jalving M, Lee R, Lorigan P, Marquez-Rodas I, Michelin O, Nathan P, Robert C, Schadendorf D, Sobczuk P, Flatz L, Leiter U, Garbe C

doi: 10.1016/j.ejca.2024.115160

Further Publications

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

J Natl Cancer Inst

Zerdes I, Filis P, Fountoukidis G, El-Naggar AI, Kalofonou F, D'Alessio A, Pouptsis A, Foukakis T, Pentheroudakis G, Ahlgren J, Smith D, Valachis A

doi: 10.1093/jnci/djaf015

Skin Cancer

Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study

Eur J Cancer

Schadendorf D, Lord-Bessen J, Ejzykowicz F, Shi L, Yu P, Srinivasan S

doi: 10.1016/j.ejca.2024.115099

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

Breast Cancer

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Eur J Cancer

Molinelli C, Bruzzone M, Blondeaux E, Ruelle T, Lanzavecchia C, De Laurentiis M, Russo S, Riccardi F, Sini V, Cognetti F, Arpino G, Fabi A, Pugliese P, Collovà E, Fontana A, Puglisi F, Bighin C, Lambertini M, Del Mastro L

doi: 10.1016/j.ejca.2024.115113

ASH 2024

Lymphoma

Related content

Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors

Results of TRODELVY® real-world data

Health-Related Quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared to ipilimumab in a randomized phase 3 trial

A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research

Comprehensive Genome Profiling for Treatment Decisions in Patients with Metastatic Tumors: Real-World Evidence Meta-Analysis and Registry Data Implementation

Prognostic value of patient-reported outcomes in advanced or metastatic melanoma patients treated with immunotherapy: Findings from the CheckMate-067 study

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

The journey of patients affected by metastatic hormone receptor-positive/HER2-negative breast cancer from CDK 4/6 inhibitors to second-line treatment: A real-world analysis of 701 patients enrolled in the GIM14/BIOMETA study

Real-world data support the use of axi-cel as a second-line therapy in patients with R/R LBCL

Results of TRODELVY^® real-world data